Drug Description in Trials / DrugBank / KEGG DRUG
Search results
No. | Drug (Description in trials) | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | Disease ID |
---|---|---|---|---|---|---|
1 | All patients in the study will be treated with ocrelizumab | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 |
2 | Continued Ocrelizumab | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 |
3 | OCRELIZUMAB | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [3] 13 13, 46, 49 |
4 | Ocrelizumab (CinnaGen, Iran) | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 |
5 | Ocrelizumab (Roche, Switzerland) | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 |
6 | Ocrelizumab / rhuMAb 2H7 | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 46 46 |
7 | Ocrelizumab 300 mg | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 |
8 | Ocrelizumab 300mg | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 |
9 | Ocrelizumab 300mg /10ml | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 |
10 | Ocrelizumab 300mg/10 ml | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 |
11 | Ocrelizumab 300mg/10ml | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 |
12 | Ocrelizumab 500mg | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 46 46 |
13 | Ocrelizumab 600 mg | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 |
14 | Ocrelizumab at home | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 |
15 | Ocrelizumab Dose 1 | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 |
16 | Ocrelizumab Dose 2 and Dose 3 | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 |
17 | Ocrelizumab IV | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 |
18 | Ocrelizumab SC | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 |
19 | Ocrelizumabu 200mg | - | - | - | - | [1] 46 46 |
20 | Ocrelizumabu 50mg | - | - | - | - | [1] 46 46 |
21 | Other: Observation of Ocrelizumab as Treatment in RRMS Patients | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 |
22 | Other: Ocrelizumab | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 |
23 | Short-course Ocrelizumab | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
(Name: Ocrelizumab) | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 |